کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
3419178 | 1225805 | 2007 | 6 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Voriconazol como terapia de las micosis en receptores de Trasplantes de Ãrganos Sólidos
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
موضوعات مرتبط
علوم زیستی و بیوفناوری
ایمنی شناسی و میکروب شناسی
میکروب شناسی
پیش نمایش صفحه اول مقاله
![عکس صفحه اول مقاله: Voriconazol como terapia de las micosis en receptores de Trasplantes de Ãrganos Sólidos Voriconazol como terapia de las micosis en receptores de Trasplantes de Ãrganos Sólidos](/preview/png/3419178.png)
چکیده انگلیسی
Invasive fungal infections (IFI) are the third cause of infectious complications in recipients of solid organ transplants (SOT), showing an incidence of 5-42% depending of the trasplanted organ. Moreover, IFI account for significant morbility and mortality in SOT, ranging between 25-95% depending on the type of fungus and its organ localization. Different strategies (prophylaxis, preemptive treatment, treatment, antifungal combinations, routes of administration) have been tested to improve the prognosis of IFI in SOT. To reach this objective, it was essential to have access to new antifungals showing a higher spectrum of activity on the fungal pathogens, both classical and emerging, and showing improvements in pharmacokinetic and pharmacodynamic characteristics, ease of administration and acceptability and lower rates of adverse effects. Introduction of voriconazole in the therapeutic arsenal has facilitated to reach these goals due to its special pharmacological characteristics, its in vitro antifungal activity and the in vivo clinical efficacy demonstrated in different studies.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Revista Iberoamericana de MicologÃa - Volume 24, Issue 3, September 2007, Pages 217-222
Journal: Revista Iberoamericana de MicologÃa - Volume 24, Issue 3, September 2007, Pages 217-222
نویسندگان
Amparo Solé, Miguel Salavert,